Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Authors
Keywords
-
Journal
LEUKEMIA
Volume 25, Issue 5, Pages 749-760
Publisher
Springer Nature
Online
2011-02-04
DOI
10.1038/leu.2011.3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
- (2010) Stephen A. Schey et al. BRITISH JOURNAL OF HAEMATOLOGY
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
- (2010) Meletios Dimopoulos et al. CANCER
- Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program
- (2010) Evelien Kneppers et al. Clinical Lymphoma Myeloma & Leukemia
- Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
- (2010) A. K. Gandhi et al. CURRENT CANCER DRUG TARGETS
- Meeting the Unmet Needs in Anticoagulant Therapy
- (2010) EUROPEAN JOURNAL OF HAEMATOLOGY
- Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study
- (2010) Javier De La Rubia et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
- (2010) J.-L. Harousseau et al. HAEMATOLOGICA
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
- (2010) M A Dimopoulos et al. LEUKEMIA
- Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
- (2010) Heinz Ludwig et al. Nature Reviews Clinical Oncology
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- Risky business in myeloma
- (2009) S. Lonial BLOOD
- Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
- (2009) S. Knop et al. BLOOD
- Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
- (2009) P. Kapoor et al. BLOOD
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
- (2009) P. Richardson et al. BLOOD
- Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
- (2009) A. Hoering et al. BLOOD
- Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
- (2009) Christine Chen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma
- (2009) Niels W.C.J. van de Donk et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
- (2009) Edward A. Stadtmauer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204)
- (2009) Mohamad A. Hussein et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone
- (2009) Maurizio Zangari et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Treatment of Myeloma: Cure vs Control
- (2009) S. Vincent Rajkumar MAYO CLINIC PROCEEDINGS
- Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
- (2008) Ulrike Klein et al. ANNALS OF HEMATOLOGY
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
- (2008) Antonio Palumbo et al. BLOOD REVIEWS
- Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
- (2008) María-Victoria Mateos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Pathogenesis and treatment of renal failure in multiple myeloma
- (2008) M A Dimopoulos et al. LEUKEMIA
- Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update
- (2007) J. Douglas Rizzo et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search